Logotipo del repositorio
 

Human papillomavirus (HPV) vaccination : from clinical studies to immunization programs

Vista sencilla de ítem
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Preventiva y Social. Grupo de investigación de Medicina Preventiva y Social
dc.contributor.javerianateacherMurillo, Raul
dc.contributor.javerianateacherOrdóñez- Reyes, Camila
dc.date.accessioned2020-12-05T15:56:06Z
dc.date.available2020-12-05T15:56:06Z
dc.date.created2019-08-26
dc.description.abstractenglishCervical cancer incidence and mortality have decreased in high-income countries, but low- and middle-income countries continue to bear a significant burden from the disease. Human papillomavirus (HPV) vaccines are a promising alternative for disease control; however, their introduction is slow in settings with greater need. We conducted a review of HPV vaccine efficacy and effectiveness reported in clinical trials and population-based studies. Efficacy of HPV vaccines is close to 100% when using a three-dose schedule in HPV-negative young women (<25 years old) for protection against persistent infection and HPV vaccine-type associated pre-cancerous lesions. Furthermore, sustained protection for up to 12 years of follow-up has been demonstrated; cross-protection against non-vaccine types is particularly observed for the bivalent vaccine, and preliminary data regarding impact on invasive cancer have emerged. Given its lower efficacy, catch-up vaccination beyond 19 years of age and proposals for vaccinating adult women deserve careful evaluation in accurately designed studies and economic analyses. Despite positive results regarding immunogenicity and post-hoc analysis for cervical intra-epithelial neoplasia in clinical trials, population-based data for prime and booster two-dose schedules are not available. Evaluation of vaccine safety from surveillance systems in immunization programs that have already distributed more than 270 million doses found no association of HPV vaccination with serious side effects. The introduction of HPV vaccination in national immunization programs remains the main challenge in tackling the burden of cervical cancer (up to 2018, only 89 countries have introduced vaccination worldwide, and most of these are high-income countries). Access models and technical capacity require further development to help low- and middle-income countries to increase the pace of vaccine delivery. Alternative approaches such as one-dose schedules and vaccination at younger ages may help reduce the programmatic and economic challenges to adolescent vaccination.spa
dc.description.indexingRevista Internacional - Indexadaspa
dc.description.orcidhttps://orcid.org/0000-0001-7187-9946spa
dc.description.quartilescopusQ1spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.identifierhttps://login.ezproxy.javeriana.edu.co/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=edo&AN=139730125&lang=es&site=eds-livespa
dc.identifier.doihttp://dx.doi.org/10.1136/ijgc-2019-000582spa
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.issn1048-891X / 1525-1438 (Electrónico)spa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.identifier.urihttp://hdl.handle.net/10554/51945
dc.language.isoengspa
dc.relation.citationendpage1326spa
dc.relation.citationissue8spa
dc.relation.citationstartpage1317spa
dc.relation.citationvolume29spa
dc.relation.ispartofjournalInternational Journal of Gynecological Cancerspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.keywordCervical intraepithelial neoplasiaspa
dc.subject.keywordClinical efficacyspa
dc.subject.keywordImmunisation programsspa
dc.subject.keywordPapillomavirus vaccinesspa
dc.subject.keywordPopulation impactspa
dc.subject.keywordPrimary preventionspa
dc.subject.keywordSafetyspa
dc.subject.keywordUterine cervical neoplasmsspa
dc.titleHuman papillomavirus (HPV) vaccination : from clinical studies to immunization programsspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
murillo2019.pdf
Tamaño:
543.63 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos